43
Participants
Start Date
December 1, 2021
Primary Completion Date
March 30, 2026
Study Completion Date
March 30, 2026
Cladribine
5mg/㎡/day d1-5 in 2 hours, before the use of Cytarabine
G-CSF
5ug/kg/day d0-5,if Peripheral blood leukocytes\<20,000/ul
Cytarabine
2g/㎡/day d1-5 in 4 hours, after the use of Cladribine
Idarubicin
Idarubicin 10mg/m2/day or mitoxantrone 10mg/m2/day on day 1-3 in the induction therapy II
Mitoxantrone
Idarubicin 10mg/m2/day or mitoxantrone 10mg/m2/day on day 1-3 in the induction therapy II
Sorafenib
200mg/m2/day was taken orally until molecular biology remission for 2 years
RECRUITING
Maternal and Child Health Hospital of Foshan, Foshan
RECRUITING
Guangzhou First People's Hospital, Guangzhou
RECRUITING
The First Affiliated Hospital of Guangzhou Medical University, Guangzhou
RECRUITING
Third Affiliated Hospital, Sun Yat-Sen University, Guangzhou
RECRUITING
Zhujiang Hospital of Southern Medical University, Guangzhou
RECRUITING
Guangzhou First People's Hospital First Affiliated Hospital of Shantou University Medical College, Shantou
RECRUITING
Second Xiangya Hospital of Central South University, Changsha
RECRUITING
Jiangxi Province Children's Hospital Southern Medical University, China, Nanchang
RECRUITING
The First Affiliated Hospital of Nanchang University, Nanchang
Third Affiliated Hospital, Sun Yat-Sen University
OTHER
Maternal and Child Health Hospital of Foshan
OTHER
The First Affiliated Hospital of Guangzhou Medical University
OTHER
Second Xiangya Hospital of Central South University
OTHER
Jiangxi Province Children's Hospital
OTHER
Southern Medical University, China
OTHER
The First Affiliated Hospital of Nanchang University
OTHER
Guangzhou First People's Hospital
OTHER
First Affiliated Hospital of Shantou University Medical College
OTHER
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
OTHER